Clinical trials: Patient With Colorectal Cancer
Colorectal Cancer
Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00062426
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- 52 sites in United States
- Sponsor
- Prologue Research International
Renal Cell Carcinoma, Melanoma
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200603 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer
- Trial name
- NCT05789069
- Testing
- HFB200603, Tislelizumab
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 83 people
- Sponsor
- HiFiBiO Therapeutics
Metastatic Colorectal Cancer
Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC
Trial design: Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic acid-Irinotecan" or "HA-Irinotecan") regimen. Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.
- Trial name
- FOLF(HA)iri (NCT01290783)
- Testing
- Irintoecan, HA-Irinotecan solution for Infusion
- Where
- 5 sites in Australia
- Volunteers
- 390 people
- Sponsor
- Alchemia Oncology
Colorectal Cancer
Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005979
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 30 sites in France
- Sponsor
- UNICANCER
Colorectal Cancer
Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00392470
- Testing
- cetuximab, irinotecan hydrochloride, conventional surgery
- Where
- 3 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Cancer of Rectum, Lymph Node Disease
Survival of Patients With a Reduction in the Number of Lymph Nodes in Rectal Cancer After Neoadjuvant Chemoradiotherapy
Objective: To analyze the survival of patients with a reduction in the number of resected LN in patients submitted to neoadjuvant and total excision of the mesorectum with rectal cancer.
- Trial name
- NCT04456283
- Testing
- Survival
- Where
- Brazil
- Volunteers
- 250 people
- Sponsor
- University of Sao Paulo
Rectal Cancer
Bowel Preparation Before Rectal Cancer Surgery
Traditionally bowel preparation before surgery of rectal cancer could be troublesome for patients especially for patients with kidney and cardio- vascular diseases, where salt and electrolyte balance can be a problem.
- Trial name
- NCT00687570
- Testing
- Fresubin Energy Drink, Laxabon®
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Karolinska Institutet
Colorectal Adenocarcinoma Metastatic in the Liver, Liver Metastasis Colon Cancer
Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis
The goal of this clinical trial is to assess how many patients with initially inoperable colorectal liver metastasis are able to have a liver surgery after treatment with hepatic artery infusion chemotherapy and standard of care…
- Conditions
- Colorectal Adenocarcinoma Metastatic in the Liver, Liver Metastasis Colon Cancer, Liver Metastases From Colorectal Cancer, Liver Metastases of Colorectal Cancer
- Trial name
- HAIP-6192 (NCT07764497)
- Testing
- Floxuridine (FUDR)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Sunnybrook Health Sciences Centre
Colorectal Cancer
Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
This study evaluates the relationship of biomarker expression and efficacy of bevacizumab plus chemotherapy in patients with unresectable/metastatic colorectal cancer.
- Trial name
- NCT01679327
- Testing
- Oxaliplatin, Xeloda, Calcium folinate (CF)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer
Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
This study will evaluate the efficacy of Irinotecan,Capecitabine and Avastin combination in patients with no response to previous treatment with 5-Fluorouracil,Leucovorin,Eloxatin and Avastin.
- Trial name
- NCT00717990
- Testing
- Capecitabine, Bevacizumab, Irinotecan
- Where
- Greece
- Volunteers
- 15 people
- Sponsor
- University Hospital of Crete
Colon Cancer
Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients
Among women with HNPCC, this study will assess: 1. Knowledge of screening recommendations for endometrial and ovarian cancers. 2. Perceived risk and cancer worries regarding endometrial, ovarian and colorectal cancers. 3.
- Trial name
- NCT00508846
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- M.D. Anderson Cancer Center
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma, Glioblastoma
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer
- Trial name
- NCT04270461
- Testing
- NKG2D-based CAR T-cells
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Jiujiang University Affiliated Hospital
Colorectal Cancer Stage II and III
Fuzheng Yiliu-1010
Real world study was used to evaluate the therapeutic effect of Fuzheng anti-tumor therapy on colorectal cancer patients in stage II and III after surgery and standard chemotherapy, and the prediction model of dominant population…
- Trial name
- NCT04459754
- Testing
- Fuzheng Yiliu Formulation
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of cetuximab when given together with pembrolizumab in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other…
- Conditions
- Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02713373
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Roswell Park Cancer Institute
Oesophageal Cancer, Gastric Cancer
Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients
The purpose of this study is to assess the efficacy of modulated mid-frequency whole-body electromyostimulation (WB-EMS) combined with nutritional therapy in patients with gastrointestinal cancer.
- Conditions
- Oesophageal Cancer, Gastric Cancer, Duodenal Cancer, Colorectal Cancer
- Trial name
- MOMENT (NCT06414122)
- Testing
- mid-frequency whole-body electromyostimulation (WB-EMS), conventional exercise training, nutritional therapy
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- University of Cologne
Advanced Breast Cancer, Advanced Prostate Cancer
Engage Psychosocial Intervention for Cancer Symptoms
The goal of this clinical trial is to test the efficacy a new psychosocial symptom management intervention called ENGAGE for patients with Stage IV breast, prostate, lung, or colorectal cancer.
- Conditions
- Advanced Breast Cancer, Advanced Prostate Cancer, Advanced Lung Cancer, Advanced Colorectal Carcinoma
- Trial name
- Engage (NCT06555588)
- Testing
- ENGAGE, Supportive Care
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- Duke University
Colorectal Cancer, Gut Microbiota
Modified MAC Diet and Gut Microbiota in CRC Patients
To explore the changes in the composition and diversity of intestinal microbiota during 3-weeks of modified MAC diet and conventional diet in stage I or low-risk stage II colorectal cancer (CRC) patients after surgery.
- Conditions
- Colorectal Cancer, Gut Microbiota, Diet Intervention
- Trial name
- NCT05039060
- Testing
- Modified MAC diet (3-weeks)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Korea University Anam Hospital
Metastatic Colorectal Cancer, pMMR
Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
The main objective of the SIRTCI study is to evaluate the safety and efficacy of the combination chemotherapy (XELOX: Capecitabine plus oxaliplatin), anti-angiogenic (Bevacizumab), SIRT (TheraSphere®) and ICI (Atezolizumab) in…
- Conditions
- Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor
- Trial name
- SIRTCI (NCT04659382)
- Testing
- Atezolizumab, Therasphere, XELOX
- Where
- 19 sites in France
- Volunteers
- 52 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.